Skip Navigation


BJA Advance Access originally published online on May 19, 2009
British Journal of Anaesthesia 2009 103(1):7-13; doi:10.1093/bja/aep125
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
103/1/7    most recent
aep125v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Diemunsch, P.
Right arrow Articles by Brichant, J.-F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diemunsch, P.
Right arrow Articles by Brichant, J.-F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author [2009]. Published by Oxford University Press on behalf of The Board of Directors of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournal.org

Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting

P. Diemunsch1,*,{dagger}, G. P. Joshi2 and J.-F. Brichant3

1 Department of Anesthesiology, Hautepierre University Hospital, 1, Avenue Molière, 67000 Strasbourg, France
2 Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, TX, USA
3 Department of Anesthesiology and Intensive Care, Service d'Anesthésie—Réanimation Chirurgicale, University Hospital of Liège, Belgium

* Corresponding author. E-mail: pierre.diemunsch{at}chru-strasbourg.fr

Despite major advances, emesis remains a major problem in the context of cancer chemotherapy and in the postoperative period. A better understanding of the relevant neurocircuitry, especially the central pattern generator responsible for emesis and the central role of substance P, led to the development of a new class of antiemetics: the neurokinin-1 (NK1) receptor antagonists. Aprepitant is the first NK1 receptor antagonist approved for use in postoperative nausea and vomiting, but several other compounds are currently being investigated for their potential as antiemetics in the postoperative and cancer chemotherapy settings.

Keywords: antagonists, NK1 receptor, aprepitant; complications; substance P; vomiting, nausea

{dagger} Declaration of interest. P.D. has acted as a lecturer, consultant, investigator, and coordinator of clinical studies promoted by Glaxo, Marion Merrell Dow, Roche, Pro Strakan, Merck.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
D. J. Rowbotham
Neurokinin-1 antagonists: a step change in prevention of postoperative nausea and vomiting?
Br. J. Anaesth., July 1, 2009; 103(1): 5 - 6.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.